Passage Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$11.34next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly33.3MTarget: Sufficient capital to sustain operations through strategic review
Workforce Reduction Progress Quarterly0.8Target: 1.00 (Complete 75% headcount reduction)
CSF Progranulin (PGRN) Level (Dose 1 at 12 Months) Annually22.8Target: Maintain durable elevation above baseline (<3 ng/mL)
Watch Items
- Strategic Alternatives Review OutcomeTrigger: Board approval of a merger, acquisition, reverse merger, asset sale, or partnershipAction: Evaluate transaction terms, valuation, and survival prospects of the combined entity
- Going Concern StatusTrigger: Cash runway drops below 6 months without non-dilutive or dilutive financingAction: Assess liquidation risk or potential restructuring under bankruptcy protection
- PBFT02 Clinical Development PathTrigger: Decision to completely terminate or partner the FTD-GRN and FTD-C9orf72 programsAction: Re-evaluate the long-term investment thesis and pipeline valuation
Research as of 20 Jun 2026